Thyreosvaccines
1 known investors
Find your way into Thyreosvaccines
Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $297.5K |
| Department of Agriculture (USDA) | Phase I | 2022 | $174.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Thyreosvaccines do?
- Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.
- Who are Thyreosvaccines's investors?
- Thyreosvaccines's investors include Invest Nebraska.